Part the Cloud Translational Research for Alzheimer’s Disease Program
Funds early-stage clinical trials of novel or repurposed therapeutics for Alzheimer’s, emphasizing translational research and accelerating promising treatments into clinical testing.
Funder: Alzheimer's Association
Due Dates (Anticipated): March 2027 (Letter of Intent) | April 2027 (Full application)
Funding Amounts: Up to $1,000,000 total costs over 2–3 years; indirect costs capped at 10% for non-profits only.
Summary: Supports early-stage human clinical trials of novel or repurposed therapeutics for Alzheimer’s disease and related dementias, with an emphasis on translational research.
Key Information: Letter of Intent required; open internationally to academic and small company investigators.
Description
This program provides targeted funding for early-stage human clinical trials (Phase 1 and 2) evaluating novel or repurposed medications for Alzheimer’s disease and related dementias. Projects may include lead candidate therapeutics requiring early testing, pilot proof-of-mechanism studies, small-scale Phase 2a studies for repurposed drugs, or proof-of-concept biomarker validation. The initiative aims to bridge the funding gap between preclinical development and larger efficacy trials, accelerating the translation of promising therapeutics into clinical testing. Both academic investigators and small companies are eligible, and proposals must be translational in nature, clearly outlining the intended measures, methods, and clinical relevance.
